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Résumé en
anglais
Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate
systems. This study examined lipid nanocapsules for their oral absorption potential
as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase
inversion method and cationic surfactants such as hexadecyltrimethyl ammonium
bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded
with Fp on their surface, were prepared and characterized (zeta potential, size and
Fp association efficiency and content). In vivo studies were conducted after single
oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the
concentration of Fp in the plasma was measured by anti-factor Xa activity assay.
The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings
demonstrated linear pharmacokinetic profiles of the drug with an increased oral
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